Patent application number | Description | Published |
20090143374 | Use of Compounds and Compositions for the Treatment of Amyloid Diseases - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, use in the reduction of Aβ peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase. | 06-04-2009 |
20090214555 | Proteoglycan Splice Variants as Therapeutics and Diagnostics for Amyloid Diseases - The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease. | 08-27-2009 |
20090253637 | SMALL PEPTIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER BETA-AMYLOID PROTEIN DISORDERS - Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease. | 10-08-2009 |
20110015272 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases - This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection. | 01-20-2011 |
20110275080 | PROTEOGLYCAN SPLICE VARIANTS AS THERAPEUTICS AND DIAGNOSTICS FOR AMYLOID DISEASES - The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease. | 11-10-2011 |
20150038591 | Compounds, compositions and methods for the treatment of tauopathies - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of tauopathies, such as Alzheimer's disease and Parkinson's disease, and the manufacture of medicaments for such treatment. | 02-05-2015 |
Patent application number | Description | Published |
20100168843 | Coating For Implantable Devices And A Method Of Forming The Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 07-01-2010 |
20100198339 | Coating for Implantable Devices and a Method of Forming the Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 08-05-2010 |
20100198340 | Coating for Implantable Devices and a Method of Forming the Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 08-05-2010 |
20100198341 | COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 08-05-2010 |
20100198342 | COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 08-05-2010 |
20100198343 | COATING FOR IMPLANTABLE DEVICES AND A METHOD OF FORMING THE SAME - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 08-05-2010 |
20110070283 | Coating For Implantable Devices And A Method Of Forming The Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients. | 03-24-2011 |
20120185034 | Coating For Implantable Devices And A Method Of Forming The Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can serve as a primer coating for subsequent coatings that can be used for the delivery of an active ingredient or a combination of active ingredients. | 07-19-2012 |
Patent application number | Description | Published |
20100167268 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject. | 07-01-2010 |
20110117056 | DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV. | 05-19-2011 |
20110151431 | DETECTION OF XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV nucleic acid in a sample from a subject. | 06-23-2011 |
20110311484 | STRAINS OF XENOTROPIC MURINE LEUKEMIA-RELATED VIRUS AND METHODS FOR DETECTION THEREOF - Provided are novel strains of Xenotropic Murine Leukemia Virus-Related Virus (XMRV), or polynucleotides or polypeptides thereof. Identified herein are nucleic acid changes or amino acid changes identified in XMRV strains isolated from subjects. Also provided are methods of detecting such XMRV strains based at least in part on the identified nucleic acid changes or amino acid changes. | 12-22-2011 |
20130309245 | USING A CYTOKINE SIGNATURE TO DIAGNOSE DISEASE OR INFECTION - Provided are methods and compositions for detection of levels, activity, or expression of cytokines so as to determine a cytokine signature. A cytokine signature of a subject can be compared to a control or reference value(s) and differences there between used in the diagnosis or monitoring of a neuroimmune disease or a retroviral infection. | 11-21-2013 |